Smartinhaler maker Adherium has announced a collaboration with pulmonary disease management provider Vitalus Health for promotion of Adherium’s inhaler monitoring technology to COPD patients in the southwest US.
In September 2017, Adherium’s SmartTouch sensor received 510(k) clearance from the FDA for use with the Symbicort inhaler, and in March 2018, the SmartTouch for Symbicort received clearance for OTC sales.
Adherium CEO Arik Anderson commented, “We’re delighted to commence this relationship with Vitalus. Establishing relationships with leading healthcare providers focused on improved patient care through better compliance is a key component of our strategy in the US. Clinical results and patient usage to date have clearly demonstrated the benefit of adherence to disease management, patient outcomes, and reduced costs to the healthcare system.”
Anderson added, “Vitalus Health and Adherium share a vision for stronger association between patients and physicians by making adherence to personal management plans easier. Together we will provide clinically-proven monitoring to support patients in adopting their physicians’ guidance into their daily lives.”
Vitalus Health CEO K. Cody Patel said, “Our company is focused on making disease management easy and smart. Our philosophy of ‘breathe well, sleep well, be well’ is at the core of our forward-thinking care management programs in the areas of sleep, neuro-diagnostics, breathing, and home health. We’ve selected Adherium as our respiratory partner because its adherence technology fits naturally within our practice and allows us to continue to make care, and the independence of our patients, seamless.”
Read the Adherium press release.
